Stocks rose sharply on Monday, Sept. 11, as Hurricane Irma's preliminary damage wasn't as devastating as some had predicted and North Korea didn't perform any nuclear tests over the weekend.
The Dow Jones Industrial Average was up more than 200 points, or 0.97%, and traded above 22,000 for the first time since Sept. 1. The S&P 500 rose 0.89% and the Nasdaq jumped more than 1.2%.
Hurricane Irma lost some of its steam over the weekend and was downgraded to a Tropical Storm early Monday as it moved along the Florida coastline and into the southeastern U.S. The National Hurricane Center said that although Irma is no longer classified as a hurricane, it is still producing wind gusts that are nearing hurricane-force.
Irma's strong gusts and powerful storm surge still caused life-threatening conditions, but maximum sustained wind speeds fell to 70 mph from Irma's peak wind speed of 185 mph late last week. The threshold for a storm to become a hurricane is 74 miles per hour. Irma is expected to continue to weaken as it moves further inland. The storm will reach the Florida panhandle Monday afternoon and move into Georgia and Alabama Monday night and into Tuesday.
Still, Irma the hurricane swamped much of downtown Miami and toppled at least three constructions cranes -- two over downtown Miami and one in Fort Lauderdale, the Associated Press reported.
According to the governor's office in Florida, about 5.7 million homes and businesses in the state lost power, CNN reported, and utility officials said it could take weeks to restore electricity to everyone.
Two tornadoes reportedly touched down in Brevard County, Florida, destroying mobile homes. No injuries have yet been reported as a result of the cyclones.
Bryan Koon, Florida's emergency management director, said late Sunday, Sept. 10, that authorities had only scattered information about the storm's toll.
"I've not heard of catastrophic damage. It doesn't mean it doesn't exist. It means it hasn't gotten to us yet," Koon told the AP.
At least one person was found dead in Orange County, Florida, as a result of a traffic accident during the storm, police said, according to CNN.
AIR Worldwide, a risk modeling software company, projected that Irma will create combined insured losses of $20 billion to $65 billion. Before Irma made landfall, Barclays forecasters predicted damages in line with Hurricane Katrina in 2005, which cost about $50 billion in insured damages.
Enki Research analyst Chuck Watson cut his damage estimates for Irma to about $49 billion. Watson had previously said on Sunday, Sept. 10, that Irma's current cost looked "pretty grim," and estimated as much as $172 billion in total U.S. damage, according to CNN Money.
More than 12,000 flights across the globe were grounded as a result of Irma. Florida's largest airport, Miami International, sustained "significant water damage" that has suspended flights, according the the airport's CEO.
Irma is also projected to hit Atlanta late Monday and early Tuesday, which could ground thousands of Delta Air Lines Inc. (DAL - Get Report) flights at the company's hub and the world's busiest airport. American Airlines Group Inc. (AAL - Get Report) said it plans to resume flights from its Miami hub Tuesday.
New York Federal Reserve President William Dudley said on Friday, Sept. 8, that it's too soon to judge the timing of a Fed rate hike, due in part to the fact that Hurricanes Harvey and Irma might result in a negative impact on the economy in the short term.
Investors were concerned last week that insurers with heavy exposure to Florida would falter as the storm took a toll. But Universal Insurance Holdings Inc. (UVE - Get Report) stock jumped 12.1% and Travelers Cos. (TRV - Get Report) rose 3% in early trading on Monday. Federated National Holdings Co. (FNHC - Get Report) was higher 13% and Allstate Corp. (ALL - Get Report) rose 1.9%.
Exchange-traded funds that track insurance stocks also snagged gains early Monday. The SPDR S&P Insurance ETF (KIE - Get Report) gained 2.2% and the iShares U.S. Insurance ETF (IAK - Get Report) was up 1.8%. The PowerShares KBW Property & Casualty Insurance Portfolio (KBWP - Get Report) was up 3.3% to mark its largest one-day gain since November of 2011.
At the same time, geopolitical concerns quieted some as North Korea didn't launch any missiles during its Foundation Day celebration Saturday, Sept. 9. The country carried out a nuclear test on the public holiday last year, prompting investors to prepare for similar action this weekend.
Foundation Day celebrated the rogue nation's 69th founding anniversary this year and is one of the most important holidays in North Korea. Celebrations came and went with no test, as Pyongyang instead held gala party for the scientists involved in creating the intercontinental ballistic missiles North Korea has been testing.
As major risk concerns abated some over the weekend, gold prices dropped 0.9%, or $12.10, to $1,339.10 per pound.
The new iPhone celebrates the 10th anniversary of the company's best-selling product.
Tesla performed an automatic update on Model S/X60/60D vehicles that unlocked the full capacity of the 75kWh battery, according to a report from Electrek. The update allowed for an extra 30 to 40 miles of driving.
Tesla used to offer the option to buy a Model S or Model X with a 75 kWh battery pack software-locked at a capacity of 60 kWh. Customers could then pay between $4,500 and $9,000 to unlock the extra 20%, depending on the model and time of the upgrade.
Tesla confirmed that it had given the extra mileage to drivers in the path of Hurricane Irma until Sept. 16, after a Model S driver contacted the company saying he would need around another 30 miles of range to evacuate in traffic.
About 5.6 million people were ordered to evacuate in Florida as Hurricane Irma barreled down on the state.
Shares of drugmaker AstraZeneca PLC (AZN - Get Report) rose 1.8% early Monday after the company said a study of its key lung cancer treatment showed stronger-than-expected results in patients who had not progressed following chemotherapy.
AstraZeneca's Imfinzi (durvalumab) oncology drug, which treats locally-advanced, unresectable non-small cell lung cancer, improves the progression-free survival rate of patients by more than 11 months. The research was presented to the European Society of Medical Oncology Congress in Madrid.
Generic drugmaker Teva Pharmaceutical Industries Ltd. (TEVA - Get Report) was also moving higher by 17.5% Monday after the company named Kare Schultz as president and CEO. The announcement ended months of speculation about who would replace former head Erez Vigodman, who left the company in February for undisclosed reasons.
Schultz will replace Yitzhak Peterburg who has been interim CEO since February. Schultz has been president and CEO of H. Lundbeck A/S since 2015, which he joined as the company was facing the loss of critical patents. He also worked as chief operating officer of Novo Nordisk A/S.
The Israel-listed generic pharmaceutical maker on Aug. 3 cut its full-year guidance and slashed its dividend 75% owing to weaker U.S. markets and the ongoing political turmoil in Venezuela. Peterburg at the times said in the earnings release that Teva experienced accelerated price erosion and lower volume in its U.S. generics business due to "customer consolidation, greater competition as a result of an increase in generic drug approvals by the U.S. Food and Drug Administration, and some new product launches that were either delayed or subjected to more competition."
Shares of Achillion Pharmaceuticals Inc. (ACHN tanked more than 19% early Monday after Johnson & Johnson's (JNJ - Get Report) Janssen Pharmaceuticals Inc. terminated its license and collaboration pact with the New Haven, Conn.-based firm on a hepatitis C project.
Janssen Sciences Ireland UC announced Monday it has decided not to continue development of investigational hepatitis C treatment regimen JNJ-4178, pointing to the "increasing availability of a number of highly effective therapies addressing the medical need in hepatitis C." Shares of Johnson & Johnson were trading at $131.95, up 0.7%.
Achillion President and CEO Milind Deshpande expressed disappointment with Janssen's decision to discontinue hepatitis C development "given the positive data presented in phase 2a with JNJ-41781, demonstrating a 100% cure rate after only six weeks of therapy."
No economic data is scheduled to be released on Monday.
Updated from 9:40 a.m. ET
More of What's Trending on TheStreet:
- Hurricane Irma Disaster Sends Looters Descending on a Florida Foot Locker: Watch
- Apple Shares Jump on Reports of $1,000 Price Tag For Anniversary iPhone
- Hurricane Irma Spurs Price Gouging Accusations at Happiest Place on Earth Disney
- 15 Collectibles That Are Completely Worthless (Such as Your McDonald's Toys)